Cargando…

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

BACKGROUND: To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). METHODS: This randomized, double-blind phase III study (Cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kay, Jonathan, Jaworski, Janusz, Wojciechowski, Rafal, Wiland, Piotr, Dudek, Anna, Krogulec, Marek, Jeka, Slawomir, Zielinska, Agnieszka, Trefler, Jakub, Bartnicka-Maslowska, Katarzyna, Krajewska-Wlodarczyk, Magdalena, Klimiuk, Piotr A., Lee, Sang Joon, Bae, Yun Ju, Yang, Go Eun, Yoo, Jae Kyoung, Furst, Daniel E., Keystone, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863328/ https://www.ncbi.nlm.nih.gov/pubmed/33546755 http://dx.doi.org/10.1186/s13075-020-02394-7

Ejemplares similares

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis
por: Furst, Daniel E, et al.
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
por: Suh, Chang-Hee, et al.
Publicado: (2019)

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects
por: Davidson, Antonia, et al.
Publicado: (2021)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64
por: Iwaszko, Milena, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
por: Wiland, Piotr, et al.
Publicado: (2020)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study
por: Jeka, Sławomir, et al.
Publicado: (2017)

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
por: Liu, Jennifer, et al.
Publicado: (2016)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
por: Schreiber, Stefan, et al.
Publicado: (2020)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions
por: Lindemann, Carsten, et al.
Publicado: (2013)

Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome
por: Sota, Jurgen, et al.
Publicado: (2021)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

P66 Adalimumab originator versus biosimilar in children and young people with JIA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
por: Burlando, Martina, et al.
Publicado: (2022)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rsfm7l8nml96ue01vtt46q39uu